High sugar intake and development of skeletal muscle insulin resistance and inflammation in mice: A protective role for PPAR- δ agonism

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Benetti, Elisa ^a   Mastrocola, Raffaella ^a   Rogazzo, Mara ^a   Chiazza, Fausto ^a   Aragno, Manuela ^a   Fantozzi, Roberto ^a   Collino, Massimo ^a   Minetto, Marco A ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

[4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; ADENYLATE KINASE; ADIPONECTIN; CARNITINE PALMITOYLTRANSFERASE I; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; GLUCOSE TRANSPORTER 4; GLUCOSE TRANSPORTER 5; GLYCOGEN SYNTHASE KINASE 3BETA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN KINASE B; TRIACYLGLYCEROL; CARBOHYDRATE; FIBROBLAST GROWTH FACTOR; NUTRITIVE SWEETENER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GASTROCNEMIUS MUSCLE; GLUCOSE METABOLISM; HYPERINSULINEMIA; HYPERLEPTINEMIA; HYPOADIPONECTINEMIA; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; MOUSE; MUSCLE DEVELOPMENT; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SUGAR INTAKE; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; ANIMAL; C57BL MOUSE; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GLUCOSE TOLERANCE TEST; LIPID METABOLISM; METABOLISM; SKELETAL MUSCLE; AGONISTS;

ANIMALS; CARBOHYDRATES; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; GLUCOSE; GLUCOSE TOLERANCE TEST; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; LIPID METABOLISM; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; NUTRITIVE SWEETENERS; PPAR DELTA; SIGNAL TRANSDUCTION; THIAZOLES;

EID: 84880170528     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/509502     Document Type: Article

References (51)

1. Samuel V. T., Shulman G. I., Mechanisms for insulin resistance: common threads and missing links. Cell 2012 148 5 852 871 2-s2.0-84857861919 10.1016/j.cell.2012.02.017
2. Hoeks J., de Wilde J., Hulshof M. F. M., van den Berg S. A. A., Schaart G., van Dijk K. W., Smit E., Mariman E. C. M., High fat diet-induced changes in mouse muscle mitochondrial phospholipids do not impair mitochondrial respiration despite insulin resistance. PLoS ONE 2011 6 11 2-s2.0-82155192472 10.1371/journal.pone.0027274 e27274
3. Vijayakumar A., Wu Y., Sun H., Li X., Jeddy Z., Liu C., Schwartz G. J., Yakar S., LeRoith D., Targeted loss of ghr signaling in mouse skeletal muscle protects against high-fat diet-induced metabolic deterioration. Diabetes 2012 61 1 94 103 2-s2.0-84555195115 10.2337/db11-0814
4. Badin P. M., Vila I. K., Louche K., Mairal A., Marques M. A., Bourlier V., Tavernier G., Langin D., Moro C., High-fat diet-mediated lipotoxicity and insulin resistance is related to impaired lipase expression in mouse skeletal muscle. Endocrinology 2013 154 4 1444 1453 10.1210/en.2012-2029
5. Collino M., Benetti E., Rogazzo M., Mastrocola R., Yaqoob M. M., Aragno M., Thiemermann C., Fantozzi R., Reversal of the deleterious effects of chronic dietary HFCS-55 intake by PPAR- δ agonism correlates with impaired NLRP3 inflammasome activation. Biochemical Pharmacology 2013 85 2 257 264 10.1016/j.bcp.2012.10.014
6. Collino M., High dietary fructose intake: sweet or bitter life? World Journal of Diabetes 2011 2 77 81
7. Benetti E., Patel N. S. A., Collino M., The role of PPAR β / δ in the management of metabolic syndrome and its associated cardiovascular complications. Endocrine, Metabolic and Immune Disorders-Drug Targets 2011 11 4 273 284 2-s2.0-80055111435
8. Barish G. D., Narkar V. A., Evans R. M., PPAR δ: a dagger in the heart of the metabolic syndrome. Journal of Clinical Investigation 2006 116 3 590 597 2-s2.0-33644645013 10.1172/JCI27955 (Pubitemid 43326863)
9. Schuler M., Ali F., Chambon C., Duteil D., Bornert J., Tardivel A., Desvergne B., Wahli W., Chambon P., Metzger D., PGC1 expression is controlled in skeletal muscles by PPAR β whose ablation results in fiber-type switching, obesity, and type 2 diabetes. Cell Metabolism 2006 4 5 407 414 2-s2.0-33750427891 10.1016/j.cmet.2006.10.003 (Pubitemid 44645068)
10. Li L., Luo Z., Yu H., Feng X., Wang P., Chen J., Pu Y., Zhao Y., He H., Zhong J., Liu D., Zhu Z., Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator-activated receptor- δ activation. Diabetes 2013 62 3 762 774 10.2337/db12-0570
11. Cuevas-Ramos D., Aguilar-Salinas C. A., Gomez-Perez F. J., Metabolic actions of fibroblast growth factor 21. Current Opinion in Pediatrics 2012 24 4 523 529 10.1097/MOP.0b013e3283557d22
12. -/- mice. Atherosclerosis 2005 181 1 29 37 2-s2.0-20444378931 10.1016/j. atherosclerosis.2004.12.028 (Pubitemid 40804690)
13. Meldrum D. R., Shenkar R., Sheridan B. C., Cain B. S., Abraham E., Harken A. H., Hemorrhage activates myocardial NF B and increases TNF- in the heart. Journal of Molecular and Cellular Cardiology 1997 29 10 2849 2854 2-s2.0-0031257781 10.1006/jmcc.1997.0506 (Pubitemid 27466506)
14. Collison K. S., Saleh S. M., Bakheet R. H., Al-Rabiah R. K., Inglis A. L., Makhoul N. J., Maqbool Z. M., Zaidi M. Z., Al-Johi M. A., Al-Mohanna F. A., Diabetes of the liver: the link between nonalcoholic fatty liver disease and HFCS-55. Obesity 2009 17 11 2003 2013 2-s2.0-70350570495 10.1038/oby.2009.58
15. Light H. R., Tsanzi E., Gigliotti J., Morgan K., Tou J. C., The type of caloric sweetener added to water influences weight gain, fat mass, and reproduction in growing Sprague-Dawley female rats. Experimental Biology and Medicine 2009 234 6 651 661 2-s2.0-66449091481 10.3181/0812-RM-368
16. Cohen P., Goedert M., GSK3 inhibitors: development and therapeutic potential. Nature Reviews Drug Discovery 2004 3 6 479 487 2-s2.0-3042635178 (Pubitemid 38807530)
17. Taniguchi C. M., Emanuelli B., Kahn C. R., Critical nodes in signalling pathways: insights into insulin action. Nature Reviews Molecular Cell Biology 2006 7 2 85 96 2-s2.0-33244464562 10.1038/nrm1837 (Pubitemid 43278292)
18. Cross D. A. E., Alessi D. R., Cohen P., Andjelkovich M., Hemmings B. A., Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995 378 6559 785 789 2-s2.0-0029587224 10.1038/378785a0 (Pubitemid 26004411)
19. Nielsen J. N., Wojtaszewski J. F. P., Regulation of glycogen synthase activity and phosphorylation by exercise. Proceedings of the Nutrition Society 2004 63 2 233 237 2-s2.0-2942702303 10.1079/PNS2004348 (Pubitemid 38787471)
20. Bouzakri K., Zachrisson A., Al-Khalili L., Zhang B. B., Koistinen H. A., Krook A., Zierath J. R., siRNA-based gene silencing reveals specialized roles of IRS-1/Akt2 and IRS-2/Akt1 in glucose and lipid metabolism in human skeletal muscle. Cell Metabolism 2006 4 1 89 96 2-s2.0-33745668478 10.1016/j.cmet.2006. 04.008 (Pubitemid 43964475)
21. Gould G. W., Holman G. D., The glucose transporter family: structure, function and tissue-specific expression. Biochemical Journal 1993 295 part 2 329 341 2-s2.0-0027420730 (Pubitemid 23315168)
22. Zierath J. R., Nolte L. A., Wahlstrom E., Galuska D., Shepherd P. R., Kahn B. B., Wallberg-Henriksson H., Carrier-mediated fructose uptake significantly contributes to carbohydrate metabolism in human skeletal muscle. Biochemical Journal 1995 311 part 2 517 521 2-s2.0-0028807647
23. Gonzalez E., McGraw T. E., Insulin signaling diverges into Akt-dependent and -independent signals to regulate the recruitment/docking and the fusion of GLUT4 vesicles to the plasma membrane. Molecular Biology of the Cell 2006 17 10 4484 4493 2-s2.0-33749489511 10.1091/mbc.E06-07-0585 (Pubitemid 44522065)
24. Leto D., Saltiel A. R., Regulation of glucose transport by insulin: traffic control of GLUT4. Nature Reviews Molecular Cell Biology 2012 13 6 383 396 10.1038/nrm3351
25. Zeng X., Zhang C., Tong M., Chi X., Li X., Ji C., Zhang R., Guo X., Knockdown of NYGGF4 increases glucose transport in C2C12 mice skeletal myocytes by activation IRS-1/PI3K/AKT insulin pathway. Journal of Bioenergetics and Biomembranes 2012 44 3 351 355 2-s2.0-84859712319 10.1007/s10863-012-9438-z
26. Yue T., Nerurkar S. S., Bao W., Jucker B. M., Sarov-Blat L., Steplewski K., Ohlstein E. H., Willette R. N., In vivo activation of peroxisome proliferator-activated receptor- δ protects the heart from ischemia/reperfusion injury in Zucker fatty rats. Journal of Pharmacology and Experimental Therapeutics 2008 325 2 466 474 2-s2.0-42449113843 10.1124/jpet.107.135327 (Pubitemid 351574787)
27. Holmes B. F., Kurth-Kraczek E. J., Winder W. W., Chronic activation of 5′-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. Journal of Applied Physiology 1999 87 5 1990 1995 2-s2.0-0032704115
28. Musi N., Goodyear L. J., AMP-activated protein kinase and muscle glucose uptake. Acta Physiologica Scandinavica 2003 178 4 337 345 2-s2.0-0042661161 10.1046/j.1365-201X.2003.01168.x (Pubitemid 36960424)
29. Jakobsen S. N., Hardie D. G., Morrice N., Tornqvist H. E., 5′-AMP-activated protein kinase phosphorylates IRS-1 on Ser-789 in mouse C2C12 myotubes in response to 5-aminoimidazole-4-carboxamide riboside. The Journal of Biological Chemistry 2001 276 50 46912 46916 2-s2.0-0035861644 10.1074/jbc.C100483200
30. Fujii N., Ho R. C., Manabe Y., Jessen N., Toyoda T., Holland W. L., Summers S. A., Hirshman M. F., Goodyear L. J., Ablation of AMP-activated protein kinase 2 activity exacerbates insulin resistance induced by high-fat feeding of mice. Diabetes 2008 57 11 2958 2966 2-s2.0-58149348480 10.2337/db07-1187
31. Ruderman N. B., Saha A. K., Kraegen E. W., Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity. Endocrinology 2003 144 12 5166 5171 2-s2.0-0345374578 10.1210/en.2003-0849 (Pubitemid 37476042)
32. Luquet S., Lopez-Soriano J., Holst D., Fredenrich A., Melki J., Rassoulzadegan M., Grimaldi P. A., Peroxisome proliferator-activated receptor δ controls muscle development and oxidative capability. FASEB Journal 2003 17 15 2299 2301 2-s2.0-0642303113 10.1096/fj.03-0269fje (Pubitemid 39561472)
33. Tanaka T., Yamamoto J., Iwasaki S., Asaba H., Hamura H., Ikeda Y., Watanabe M., Magoori K., Ioka R. X., Tachibana K., Watanabe Y., Uchiyama Y., Sumi K., Iguchi H., Ito S., Doi T., Hamakubo T., Naito M., Auwerx J., Yanagisawa M., Kodama T., Sakai J., Activation of peroxisome proliferator-activated receptor δ induces fatty acid β -oxidation in skeletal muscle and attenuates metabolic syndrome. Proceedings of the National Academy of Sciences of the United States of America 2003 100 26 15924 15929 2-s2.0-9144271149 10.1073/pnas.0306981100 (Pubitemid 38021091)
34. Wang Y., Zhang C., Yu R. T., Cho H. K., Nelson M. C., Bayuga-Ocampo C. R., Ham J., Kang H., Evans R. M., Regulation of muscle fiber type and running endurance by PPAR δ PLoS Biology 2004 2 10, article e294 2-s2.0-8844276054 10.1371/journal.pbio.0020294 (Pubitemid 39532914)
35. Bonala S., Lokireddy S., Arigela H., Teng S., Wahli W., Sharma M., McFarlane C., Kambadur R., Peroxisome proliferator-activated receptor β / δ induces myogenesis by modulating myostatin activity. The Journal of Biological Chemistry 2012 287 16 12935 12951 2-s2.0-84859771319 10.1074/jbc.M111.319145
36. Planavila A., Rodríguez-Calvo R., Jové M., Michalik L., Wahli W., Laguna J. C., Vázquez-Carrera M., Peroxisome proliferator-activated receptor β / δ activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovascular Research 2005 65 4 832 841 2-s2.0-13844256366 10.1016/j.cardiores.2004.11.011 (Pubitemid 40249728)
37. Ding G., Cheng L., Qin Q., Frontin S., Yang Q., PPAR δ modulates lipopolysaccharide-induced TNF inflammation signaling in cultured cardiomyocytes. Journal of Molecular and Cellular Cardiology 2006 40 6 821 828 2-s2.0-33744519163 10.1016/j.yjmcc.2006.03.422 (Pubitemid 43817042)
38. Rubio-Guerra A. F., Vargas-Robles H., Serrano A. M., Vargas-Ayala G., Rodriguez-Lopez L., Escalante-Acosta B. A., Correlation between the levels of circulating adhesion molecules and atherosclerosis in hypertensive type-2 diabetic patients. Clinical and Experimental Hypertension 2010 32 5 308 310 2-s2.0-77955065607 10.3109/10641960903443533
39. Ropelle E. R., Pauli J. R., Cintra D. E., da Silva A. S., De Souza C. T., Guadagnini D., Carvalho B. M., Caricilli A. M., Katashima C. K., Carvalho-Filho M. A., Hirabara S., Curi R., Velloso L. A., Saad M. J., Carvalheira J. B., Targeted disruption of inducible nitric oxide synthase protects against aging, S-nitrosation, and insulin resistance in muscle of male mice. Diabetes 2013 62 2 466 470 10.2337/db12-0339
40. Hoeflich K. P., Luo J., Rubie E. A., Tsao M., Jin O., Woodgett J. R., Requirement for glycogen synthase kinase-3 β in cell survival and NF- B activation. Nature 2000 406 6791 86 90 2-s2.0-0034612636 10.1038/35017574 (Pubitemid 30460216)
41. Kharitonenkov A., Shiyanova T. L., Koester A., Ford A. M., Micanovic R., Galbreath E. J., Sandusky G. E., Hammond L. J., Moyers J. S., Owens R. A., Gromada J., Brozinick J. T., Hawkins E. D., Wroblewski V. J., Li D., Mehrbod F., Jaskunas S. R., Shanafelt A. B., FGF-21 as a novel metabolic regulator. Journal of Clinical Investigation 2005 115 6 1627 1635 2-s2.0-20444435873 10.1172/JCI23606 (Pubitemid 40814671)
42. Kharitonenkov A., Wroblewski V. J., Koester A., Chen Y., Clutinger C. K., Tigno X. T., Hansen B. C., Shanafelt A. B., Etgen G. J., The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007 148 2 774 781 2-s2.0-33846418834 10.1210/en.2006-1168 (Pubitemid 46143178)
43. Arner P., Pettersson A., Mitchell P. J., Dunbar J. D., Kharitonenkov A., Rydén M., FGF21 attenuates lipolysis in human adipocytes-a possible link to improved insulin sensitivity. FEBS Letters 2008 582 12 1725 1730 2-s2.0-43549110007 10.1016/j.febslet.2008.04.038
44. Li X., Ge H., Weiszmann J., Hecht R., Li Y., Véniant M. M., Xu J., Wu X., Lindberg R., Li Y., Inhibition of lipolysis may contribute to the acute regulation of plasma FFA and glucose by FGF21 in ob/ob mice. FEBS Letters 2009 583 19 3230 3234 2-s2.0-70349472910 10.1016/j.febslet.2009.09.012
45. Badman M. K., Pissios P., Kennedy A. R., Koukos G., Flier J. S., Maratos-Flier E., Hepatic fibroblast growth factor 21 is regulated by PPAR and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metabolism 2007 5 6 426 437 2-s2.0-34249711964 10.1016/j.cmet.2007.05.002 (Pubitemid 46825495)
46. Mashili F. L., Austin R. L., Deshmukh A. S., Fritz T., Caidahl K., Bergdahl K., Zierath J. R., Chibalin A. V., Moller D. E., Kharitonenkov A., Krook A., Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. Diabetes/Metabolism Research and Reviews 2011 27 3 286 297 2-s2.0-79952120254 10.1002/dmrr.1177
47. Inagaki T., Dutchak P., Zhao G., Ding X., Gautron L., Parameswara V., Li Y., Goetz R., Mohammadi M., Esser V., Elmquist J. K., Gerard R. D., Burgess S. C., Hammer R. E., Mangelsdorf D. J., Kliewer S. A., Endocrine regulation of the fasting response by PPAR -mediated induction of fibroblast growth factor 21. Cell Metabolism 2007 5 6 415 425 2-s2.0-34249686631 10.1016/j.cmet.2007.05.003 (Pubitemid 46825496)
48. Muise E. S., Azzolina B., Kuo D. W., El-Sherbeini M., Tan Y., Yuan X., Mu J., Thompson J. R., Berger J. P., Wong K. K., Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor γ and altered metabolic states. Molecular Pharmacology 2008 74 2 403 412 2-s2.0-47949111205 10.1124/mol.108.044826
49. Wang H., Qiang L., Farmer S. R., Identification of a domain within peroxisome proliferator-activated receptor γ regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Molecular and Cellular Biology 2008 28 1 188 200 2-s2.0-37549052177 10.1128/MCB.00992-07
50. Christodoulides C., Dyson P., Sprecher D., Tsintzas K., Karpe F., Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. Journal of Clinical Endocrinology and Metabolism 2009 94 9 3594 3601 2-s2.0-69949107891 10.1210/jc.2009-0111
51. Lee M. S., Choi S., Ha E. S., An S., Kim T. H., Han S. J., Kim H. J., Kim D. J., Kang Y., Lee K., Fibroblast growth factor-21 protects human skeletal muscle myotubes from palmitate-induced insulin resistance by inhibiting stress kinase and NF- B. Metabolism: Clinical and Experimental 2012 61 8 1142 1151 2-s2.0-84857670921 10.1016/j.metabol.2012.01.012